4.6 Article

Helicobacter pyloriEradication in Parkinson's Disease: A Randomized Placebo-Controlled Trial

期刊

MOVEMENT DISORDERS
卷 35, 期 12, 页码 2250-2260

出版社

WILEY
DOI: 10.1002/mds.28248

关键词

Parkinson's disease; Helicobacter pylori; small intestinal bacterial overgrowth; gastrointestinal dysfunction; gut microbiota

资金

  1. University of Malaya-Ministry of Higher Education (UM-MoHE) High Impact Research (HIR) [UM.0000017/HIR.C3, UM.C/625/1/HIR/MOE/CHAN/13/4 (H-50001-00-A000029)]
  2. University of Malaya Bantuan Kecil Penyelidikan (BKP) Research Grant [BK059-2015]

向作者/读者索取更多资源

Background Helicobacter pylori(HP) infection has been associated with worse motor function in Parkinson's disease (PD). Objective We aimed to evaluate the effects of HP eradication on PD symptoms. Methods In this parallel-group, double-blind, randomized placebo-controlled, single-center trial, patients with PD with positive HP urea breath test and serology were block randomized (1:1) to receive standard eradication triple therapy or identically appearing placebo capsules for 1 week. Prespecified motor (International Parkinson and Movement Disorder Society Unified PD Rating Scale [MDS-UPDRS], timed tests, and home-based wearable sensor measurements), nonmotor (Leeds Dyspepsia Questionnaire and Montreal Cognitive Assessment), and quality-of-life (Parkinson's Disease Questionnaire-39) outcome measures were assessed at weeks 6, 12, 24, and 52. The primary outcome was the baseline-to-week 12 change in ON medication MDS-UPDRS motor scores. Lactulose-hydrogen breath testing for concomitant small intestinal bacterial overgrowth was performed at baseline and repeated at week 24, together with the urea breath test. Results A total of 310 patients were screened for eligibility and 80 were randomly assigned, of whom 67 were included in the full-analysis set (32 treatment group patients, 35 placebo patients). HP eradication did not improve MDS-UPDRS motor scores at week 12 (mean difference 2.6 points in favor of placebo, 95% confidence interval: -0.4 to 5.6,P= 0.089). There was no significant improvement in any motor, nonmotor, or quality-of-life outcome at weeks 12 and 52. Both the full-analysis and per-protocol analyses (based on eradication status) supported these conclusions. Small intestinal bacterial overgrowth status did not influence treatment results. Conclusions HP eradication does not improve clinical outcomes in PD, suggesting that there is no justification for routine HP screening or eradication with the goal of improving PD symptoms. (c) 2020 International Parkinson and Movement Disorder Society

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据